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Abstract
Background:  Ghrelin is an orexigenic hormone principally produced by the stomach, but also by
numerous peripheral tissues including the placenta. Ghrelin acts via growth hormone secretagogue
receptors (GHSR-1a) to alter food intake, fat utilization, and cellular proliferation, and has been suggested
to play a role in the developmental growth of the fetoplacental unit. The placental expression of ghrelin
and its role in ruminant species is not known. We tested the hypotheses that ghrelin and its functional
receptor, GHSR-1a, are present in tissues of the ovine placenta, and that their expression is linked to the
stage of development.
Methods: Antibodies raised against ghrelin and GHSR-1a were used in standard immunohistochemical
protocols on placental tissues collected from pregnant ewes (n = 6 per gestational time point) at days 50,
80, 100, 128 and 135 of gestation (term ≈ day 145). Immunostaining for ghrelin and GHSR-1a was
quantified using computer-aided image analysis. Image analysis data were subjected to one-way ANOVA,
with differences in immunostaining between time-points determined by Fisher's least significant difference.
Results: Positive immunostaining for ghrelin was detected in ovine placentae at all gestational time points,
with staining localized to the maternal epithelium, caruncle and trophectoderm. There was a significant
effect of gestational age (p < 0.001) on the placental expression of ghrelin, with maximal levels at
gestational day 80. GHSR-1a immunostaining was detected in the fetal trophectoderm at all time points.
In contrast to the gestational pattern of ghrelin expression, there was no effect of gestational age on
placental GHSR-1a immunoexpression.
Conclusion:  Ghrelin and GHSR-1a are both present in the ovine placenta, and ghrelin displays a
developmentally-related pattern of expression. Therefore, these data strongly suggest that the ghrelin
system may have a role in feto-placental development in sheep.
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Background
Recent studies have indicated a role for the orexigenic hor-
mone, ghrelin, in the regulation of energy balance, food
intake and body weight in monogastric species [1-4].
Ghrelin is also involved in the regulation of growth hor-
mone (GH) secretion, being identified in 1999 as the
endogenous ligand for the GH secretagogue receptor
(GHSR-1a), a 7-transmembrane G protein coupled recep-
tor [5]. In addition to its primary origin in the stomach
[5,6], ghrelin and GHSR-1a have been found, in humans
and rats, to have a wide distribution in other tissues,
including the bowel, heart, kidney, liver, lung, pancreas,
brain, gonads and placenta [7-9]. The significance of this
wide tissue distribution has yet to be determined, how-
ever it has been suggested that ghrelin could be involved
in the control of cellular differentiation, proliferation and
apoptosis [10-15].
Although ruminant species also appear to utilise the ghre-
lin system to modulate endocrine and metabolic
responses to nutrition and energy balance [6,16-21], little
is known of the tissue distribution of ghrelin and its recep-
tor, nor of its link to developmental processes in these
species. Recently our group provided evidence to suggest
that the expression of ghrelin and its receptor are develop-
mentally regulated in the sheep fetus [22]. In adult ani-
mals, a tissue that undergoes marked development in a
relatively short space of time is the placenta. In the placen-
tae of humans and rats it has been suggested that ghrelin
plays a role in development, growth and function of the
fetoplacental unit due to the gestational-related changes
in placental expression [7,23]. Based on umbilical vein
and artery concentrations of ghrelin, Kitamura et al. [24]
suggested that a proportion of ghrelin in the circulation of
the human fetus might originate from the placenta and act
to regulate feto-maternal energy transport and growth. In
addition, ghrelin levels in the late gestation rat fetus are
unaffected by food restriction of the dam [25] even
though food restriction is known to affect maternal
plasma ghrelin levels [26]. It would appear that the late
gestation fetus is buffered, perhaps via a dominant placen-
tal or fetal source of ghrelin, against maternal changes in
ghrelin levels. However, the exact contribution and ontog-
eny of maternal versus feto-placental sources of ghrelin to
circulating fetal concentrations is unclear. The sheep pro-
vides a good animal model for investigating the possible
role of ghrelin in human placental development and func-
tion because, unlike rodent models, the temporal changes
of placental growth are similar in length to the human,
but unlike humans, there are no strict ethical constraints
on obtaining mid to late gestation ovine placental tissue.
In the present study we used immunohistochemistry to
test the hypothesis that ghrelin and its functional receptor,
GHSR-1a, are present in tissues of the ovine placenta. In
addition, we examined the ontogeny of ghrelin and
GHSR-1a immunoreactivity in the developing placenta
throughout gestation.
Materials and methods
Tissue collection and processing
All experimental procedures involving animals were con-
ducted under the authority of the Animals (Scientific Pro-
cedures) Act, UK, 1986 after Home Office and local
ethical committee approval. Singleton pregnancies in Suf-
folk x Dorset Horn x Greyface ewes were established by
embryo recovery and transfer procedures as described by
Wallace et al. [27], using the same individual Dorset Horn
sire. This technique removes the potentially confounding
influence of partial embryo loss and variation in fetal
number, and maximises the homogeneity of the resulting
fetuses. Placental tissues from ewes, nutritionally man-
aged to exhibit normal placental and fetal growth, were
collected at autopsy on days 50, 80, 100, 128 and 135 of
gestation (term ≈ day 145). These tissues (n = 6 per gesta-
tional time point) were collected as 'control' tissues from
a number of individual experiments, but all using the
same procedures and animals as described above [28-31].
The embryo donor and recipient genotypes were identical
between groups, as were the age, parity and nutritional
management of the recipient dams. A representative pla-
centome from each animal was collected for processing
for the immunohistochemical analyses. The selection of
the placentome for immunohistochemistry was based on
the picking the median sized placentome once the range
in placentome sizes for each individual animal had been
ascertained. Whole placentomes were sliced into 5 mm
cross-sections and immersion fixed in normal buffered
formalin (NBF) for 24 h. Samples were then rinsed and
stored in 70% alcohol before processing and embedding
into paraffin wax. Sections (5 μm) were cut and mounted
on polylysine coated glass slides and dried overnight at
42°C prior to immunohistochemical analysis.
Placental growth curve
Total placentome weight, with the fetal cotyledon and
maternal caruncle intact, was recorded for each animal at
each gestational time point, after carefully separating out
the individual placentomes from the placental mass [28-
31]. These data were used to construct the placental
growth curve represented in Figure 3.
Immunohistochemistry
The immunohistochemistry methods have been previ-
ously described by Miller et al. [22]. Briefly, tissue sections
were dewaxed in Histoclear (National Diagnostics, Hes-
sel, Hull, UK), rehydrated through a graded ethanol series
(100%, 95% and 70%). Antigen retrieval procedures were
necessary for exposure of all epitopes, and this was
achieved by microwaving sections in 0.01 M citrate bufferReproductive Biology and Endocrinology 2007, 5:25 http://www.rbej.com/content/5/1/25
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(pH 6.0) on full power for 3 × 5 min. To remove possible
variation arising from manual staining techniques, pla-
cental sections were placed in an Autostainer (Dako, Ely,
UK) at room temperature and incubated with the appro-
priate primary antibodies, as follows: (a) anti-human
ghrelin (Cat. H-031-30: Phoenix Europe GmbH, Karl-
sruhe, Germany) at a 1:600 dilution for 30 mins, and (b)
anti-human GHSR-1a Cys0 (330–366) (Cat. H-001-62:
Phoenix Europe GmbH, Karlsruhe, Germany) at a 1:600
dilution for 30 minutes. The negative controls were pro-
duced by substituting the primary antibody with normal
rabbit serum (ghrelin) or normal goat serum (GHSR-1a)
at the same dilution as the primary antibody. Ghrelin
detection was done using the DAKO ChemMate perioxi-
dase/DAB system (DakoCytomation Ltd, Ely, UK) and
GHSR-1a used the Vectastain Elite ABC system (Vector
Laboratories Ltd, Peterborough, UK). Antibody binding
was visualised by the ChemMate peroxidase/DAB detec-
tion system (DakoCytomation Ltd), applied in two 5
minute incubations using the Dako autostainer, and all
sections were counterstained with haematoxylin Z (Cell-
path, Hemel Hampstead, UK).
To check antibody specificity, both primary antibodies
were incubated overnight with their respective immuniz-
ing peptides. Following incubation, antibody-antigen
preparations were centrifuged and the supernatant
applied to selected placental tissue sections. We have pre-
viously published verification methods and data for the
specificity of both antibodies in stomach (abomasum)
and pituitary tissue from sheep, along with in-situ hybrid-
ization which revealed similar mRNA localization to the
peptide immunoexpression [22].
Quantification by image analysis
The expression of ghrelin and GHSR-1a was analyzed
using computer-aided image analysis. The system was
composed of a Ziess axioplan microscope (Zeiss, West
Germany) and a HV-C20 Hitachi camera (Hitachi, Japan)
connected to a computer running Image-ProPlus software
(Media Cybernetics, Maryland, USA). Sections were quan-
tified for percentage of cells that were immunopositive
(brown colour) over ten randomly selected fields of view,
which was sufficient replication to stabilise the mean and
standard error, as previously described by Murray et al.
Immunohistochemical localization of ghrelin in the sheep placenta Figure 1
Immunohistochemical localization of ghrelin in the sheep placenta. Representative immunohistochemical photomi-
crographs showing localization of ghrelin (b – f) in sheep placentomes collected at days 50 (b), 80 (c), 100 (d), 128 (e) and 135 
(f). The insert in the bottom right corner (b) represents an example of a negative control. Positive immunostaining in the pla-
centa was abolished (a) when the antiserum was pre-incubated with the immunizing peptide (ghrelin). Placentome sections 
mainly show positive immunostaining for ghrelin (brown) in the maternal compartment (M) and the trophectoderm (T), with 
few cells being immunopositive for ghrelin in the fetal compartment (F). The scale bars represent 50 μm.Reproductive Biology and Endocrinology 2007, 5:25 http://www.rbej.com/content/5/1/25
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[32]. The number of positively stained cells (brown) was
selected and expressed as a sum of pixels. All nuclei were
then selected and then the positively stained cells were
expressed as a percentage of the total.
Statistical analyses
Image analysis data were subjected to ANOVA with post-
hoc differences between placental immunostaining inten-
sity for ghrelin and GHSR-1a at different stages of gesta-
tion determined by Fisher's least significant difference.
Correlation between total placentome mass and ghrelin
expression or GHSR-1a expression was investigated by
simple regression analysis.
Results
Antibody specificity
The specificity of the two antibodies (anti-ghrelin and
anti-GHSR1a) was confirmed by the absence of immu-
nostaining when the antisera were pre-incubated with the
respective immunizing peptides (Figs. 1a &2a). Addition-
ally, immunostaining was abolished in the controls when
the primary antibodies were replaced with serum from the
species in which the antibodies were raised (inserts: Figs.
1b &2b). In all tissues investigated, the ghrelin immuno-
positive cells exhibited strong perinuclear staining and/or
more disperse cytoplasmic staining (Fig. 1). The GHSR-1a
positive cells also exhibited some perinuclear staining, but
mainly cytoplasmic staining (Fig. 2).
Ghrelin and GHSR-1a immunolocalization in placental 
tissues
Ghrelin immunoreactivity was detected in the ovine pla-
cental tissues at all of the gestational time points exam-
ined, with immunopositive staining localized to the
maternal epithelium, caruncle and the trophectoderm
(Fig. 1b–f). Placental GHSR-1a was detected mainly in the
fetal trophectoderm at all of the gestational time points
examined (Fig. 2b–f). Additionally, the blood vessels of
the ovine placenta were also immunopositive for GHSR-
1a (Fig. 2f).
Ghrelin and GHSR-1a immunoexpression throughout 
gestation
There was a significant effect of gestational age (p < 0.001)
on the percentage of cells showing positive immunoreac-
tivity for ghrelin (Fig. 3a). Placental ghrelin immunoreac-
tivity was maximal between day 50 to 100 of gestation,
reaching peak levels at day 80. At day 128, placental ghre-
Immunohistochemical localization of growth hormone secretagogue receptor (GHSR)-1a in the sheep placenta Figure 2
Immunohistochemical localization of growth hormone secretagogue receptor (GHSR)-1a in the sheep pla-
centa. Representative immunohistochemical photomicrographs showing localization of GHSR-1a (b – f) in sheep placentomes 
collected at days 50 (b), 80 (c), 100 (d), 128 (e) and 135 (f). Insert (b) represents an example of a negative control. Positive 
immunostaining in the placenta was abolished (a) when the antiserum was pre-incubated with the immunizing peptide (GHSR-
1a). Placentome sections mainly show positive immunostaining for GHSR-1a (brown) in the maternal compartment (M) and the 
trophectoderm (T), and in the blood vessels (BV). The scale bars represent 50 μm.Reproductive Biology and Endocrinology 2007, 5:25 http://www.rbej.com/content/5/1/25
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lin levels had decreased to less than half of the peak level
observed at day 80 (p < 0.01). Ghrelin immunostaining
continued to decline to day 135, the final gestational
point used in this study, with observed ghrelin levels
being less than 10% of the peak levels at day 80 (p < 0.01).
In comparison, there was no effect of gestational age on
placental GHSR-1a immunoexpression (Fig. 3c).
Placental growth throughout gestation
The change in total placentome mass with gestational age
corresponded to the changes in the percentage of cells
staining immunopositive for ghrelin (Fig. 3a). There was
a significant effect of gestational age (p < 0.001) on the
total placentome mass, which was minimum at day 50
(143 ± 22.5 g) and peaked at day 80 (657 ± 35.9 g), before
declining again at day 100 (387 ± 50.3 g) and remaining
at this lower level till day 135 (414 ± 40.8 g). There was a
significant correlation (R2 = 0.51; p < 0.05) between the
gestational change in total placentome mass and ghrelin
immunoexpression, represented graphically by compari-
son of the 2nd order polynomial lines of best fit for the two
data sets (Fig. 3b). There was no correlation between the
gestational change in total placentome mass and GHSR-
1a immunoexpression.
Discussion
The present study provides immunohistochemical evi-
dence for the presence of ghrelin and its functional recep-
tor, GHSR-1a, in placental tissues of the sheep. Novel data
are also presented that indicate that levels of ghrelin, but
not GHSR-1a, are regulated during development of the
ovine placenta. The presence of both components (ligand
and receptor) of the ghrelin signalling system in the ovine
placenta, and the changes in developmental immunoex-
pression, are consistent with a putative role of ghrelin in
placental development and function in this ruminant spe-
cies. However, it must be noted that ghrelin 'knockout'
mice are fertile and do produce normal litters [33]. How-
ever, knockout models sometimes indicate, as may be the
case here, that there are multiple systems for controlling
critical developmental process such as feto-placental
growth.
In rats and humans, Gualillo et al. [23] also demonstrated
the presence of ghrelin mRNA and protein in the placenta,
and that expression levels decreased as the placentae
developed past its peak proliferative phase. These results,
together with the present findings, strongly indicate that
the placenta is a significant source of ghrelin during mid-
gestation, and that the ghrelin ligand-receptor system may
play a role in development of the feto-placental unit in
both ruminant and non-ruminant mammals. Maternal
ghrelin levels are increased in pregnant rats that are food-
restricted from mid-pregnancy resulting in intrauterine
growth-restricted (IUGR) offspring [34]. Studies also sug-
gest that umbilical cord ghrelin levels are higher in human
small-for-gestational-age (SGA) fetuses [35,36], yet there
is no correlation between fetal and maternal ghrelin levels
in the SGA condition [37]. Bellone et al. [38] found that
ghrelin levels in human newborns are higher than those
in their mothers indicating significant feto-placental ghre-
lin production. In early pregnancy, ghrelin has been
found to inhibit the development of mouse embryos [39],
Effect of gestational age on placentomes mass and immu- noexpression of placental ghrelin and growth hormone  secretagogue receptor (GHSR)-1a Figure 3
Effect of gestational age on placentomes mass and 
immunoexpression of placental ghrelin and growth 
hormone secretagogue receptor (GHSR)-1a. Effect of 
gestational age on the percentage of cells positively immu-
nostained for ghrelin (a) and GHSR-1a (c) in sheep placen-
tomes collected between days 50 and 135 of gestation (n = 6 
at each gestational age). In Fig. 3a the change in total placen-
tome mass is superimposed as the grey line on the graph for 
ghrelin, and in Fig. 3b the comparison is shown for the 2nd 
order polynomial lines of best fit with line equations for the 
gestational change in ghrelin (black text equation, white 
squares, black line) and total placentomes mass (grey text 
equation, grey diamonds, grey line) (b). Values with different 
alphabetical superscripts are statistically significant compared 
to the peak (ghrelin) and nadir (GHSR-1a) levels at day 80: a 
versus b = p < 0.05; a versus c = p < 0.01; a versus d = p < 
0.001. Significant changes within variables over time are 
annotated to each figure. Values are means ± S.E.M.
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but in late pregnancy chronic treatment of rat mothers
with ghrelin increases birth weight of the offspring, and
rat mothers immunized against ghrelin deliver fetuses
with lower body weights [40]. Perhaps in early gestation,
high plasma concentrations of maternally-derived ghrelin
that would occur during states of malnutrition may act as
an 'embryonic termination' signal to circumvent the
excess metabolic demands of pregnancy, but in mid to
late gestation placenta-derived ghrelin in the normal con-
centration range may be essential for the growth and
development of the fetus. Further research is required to
determine the validity of these postulates.
In the present study, ovine placental ghrelin peptide
expression was maximal at gestational days 50 to 100 and
decreased to late gestation (day 135; NB: term ≈ day 147).
This observation coincided with gestational-age related
changes in total placentome mass calculated in the
present study, and also agrees with changes in placental
growth and cell proliferation in sheep gathered by other
researchers [41,42]. Peak ghrelin peptide expression
therefore corresponds to the active proliferation phase of
the placenta. Previously, we have demonstrated an associ-
ation between ghrelin immunoexpression and immuno-
histochemical markers of cell proliferation in the ovine
fetal testis [22]. Therefore, it is tempting to speculate that
ghrelin may be influencing growth of the feto-placental
unit by affecting cellular proliferation. However, data on
the effects of ghrelin upon cell proliferation are equivocal
with positive effects observed in adipocyte, cardiomyo-
cyte, osteoblast and pituitary cell lines [12,13,43,44], and
negative effects seen in breast, lung and thyroid carcinoma
cell lines [45-47]. Further studies of this postulated effect
of ghrelin on placental growth and proliferation obvi-
ously needs to be conducted as perturbation of these fac-
ets of the feto-placental unit could contribute to
developmental origins of adult disease [48]. For example,
placental size and the ratio of placental weight to birth
weight have been found to be associated with type 2 dia-
betes and impaired glucose tolerance in humans [49].
Ghrelin could be involved in the local modulation of pla-
cental GH release, which is known to affect intrauterine
development in sheep [31,50-52]. However, Fuglsang et
al. [53] found no associations between maternal ghrelin
levels and placental GH production in humans, and Kita-
mura et al. [24] found that plasma ghrelin concentrations
in human cord blood were not correlated with GH con-
centration, but they were correlated to IGF-I concentra-
tions. Alternatively, placental ghrelin could influence
maternal and/or fetal pituitary GH secretion. The admin-
istration of exogenous GH increases placental and fetal
growth, whereas a GH deficiency is associated with fetal
growth retardation [54]. Therefore, it could be hypothe-
sized that placental derived ghrelin may influence fetal
growth indirectly through modulation of pituitary GH
secretion.
Particularly evident in the sheep placental tissue was the
finding that ghrelin immunoreactivity in some cells
showed intense perinuclear staining, in cases resembling
nuclear staining. This is consistent with a previous study
by our group that also showed that the nuclei were indeed
immuno-negative when observed at high magnification
[22]. This perinuclear staining pattern may arise if the pol-
yclonal antibody is detecting the ligand/receptor complex
and is consistent with the finding of Camina et al. [55]
that the ghrelin/GHSR-1a complex progressively disap-
pears from the plasma membrane after binding of the lig-
and and accumulates in the perinuclear region.
Additionally, GHSR-1a showed positive staining in blood
vessels of the ovine placenta, in agreement with GHSR-1a
expression in adult and fetal testicular blood vessels in a
previous study [22]. It has previously been suggested that
the ghrelin ligand/receptor complex plays a role in apop-
totic control of endothelial cells through ERK1/2 and PI 3-
kinase/AKT pathways [11].
Finally, placental ghrelin may have an immunomodula-
tory role in pregnancy. For a successful pregnancy, it is
well recognised that a state of selective tolerance, immu-
nosuppression and immunomodulation in the presence
of strong anti-microbial immunity must be established
[56]. Maternal adaptation to pregnancy involves down
regulation of potentially dangerous T-cell mediated
immune responses and activation of components of the
innate immune system, such as monocytes and neu-
trophils [57]. Hattori et al. [58] found both ghrelin and
GHSR expression in human immune cells. They also
found expression of this peptide and ligand in B-cells, T-
cells and neutrophils that did not express substantial GH
transcripts suggesting that ghrelin/GHSR has biological
functions other than enhancing GH secretion in the
immune system. Wu and Kral [59] found that ghrelin
enhances immune responses and potentially down-regu-
lates anti-inflammatory molecules. Recently Dixit et al.
[60] demonstrated that ghrelin, via functional cell surface
GHSR, exerts both selective inhibitory effects on the
expression and production of the inflammatory cytokines
IL-1β, IL-6, and TNF-α by human PBMCs and T cells.
Obviously, more research is needed to elucidate whether
any of these putative actions of ghrelin, perhaps of a pla-
cental source, may play a role in immunomodulation dur-
ing pregnancy.
Conclusion
This study has demonstrated for the first time that both
ghrelin and its receptor, GHSR-1a, are present in ovine
placental tissue. Additionally, by sampling at several ges-
tational windows we have shown that maximum andReproductive Biology and Endocrinology 2007, 5:25 http://www.rbej.com/content/5/1/25
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minimum placental ghrelin immunoexpression coincides
with the time of maximum and minimum placental
growth in the sheep, respectively. This suggests a possible
role for ghrelin in the growth and/or function of the ovine
placenta and/or fetus.
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